![Lars Thomander](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lars Thomander
Corporate Officer/Principal chez
University of Uppsala
Profil
Lars Thomander is the founder of Hlt Konsult AB. He is currently an Associate Professor at the University of Uppsala.
Previously, he worked as the Chairman of CaptiGel AB, Medical Director-Nordic Region at Eli Lilly & Co., Medical Director at Abbott Scandinavia AB, Director at the Foundation for Pharmaceutical Medicine, Medical Director at AbbVie AB, Director at Double Bond Pharmaceutical International AB, and President of the Swedish Pharmaceutical Society.
Postes actifs de Lars Thomander
| Sociétés | Poste | Début |
|---|---|---|
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Lars Thomander
| Sociétés | Poste | Fin |
|---|---|---|
Abbott Scandinavia AB
 Abbott Scandinavia AB Abbott Scandinavia AB provides information on Rybelsus, the first approved oral GLP-1 receptor agonist containing semaglutide, used to treat adults with type 2 diabetes when diet and exercise alone are insufficient to control blood sugar levels. Abbott Scandinavia focuses on diabetes care and weight management, providing educational resources to patients and healthcare providers about Rybelsus’s benefits, risks, and practical considerations. The company is based in Solna, Sweden. Rybelsus works by mimicking a gut hormone to increase insulin secretion and reduce glucagon, thereby lowering blood sugar, and has also been shown to support weight loss when combined with lifestyle changes. The Swedish company ’ s content highlights the medication ’ s dosing regimen, potential side effects, precautions, and alternatives such as injectable semaglutide products. | Directeur Technique/Scientifique/R&D | 01/01/2013 |
AbbVie AB
 AbbVie AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research and development pharmaceutical company | Directeur Technique/Scientifique/R&D | 01/01/2013 |
| ELI LILLY AND COMPANY | Directeur Technique/Scientifique/R&D | - |
Foundation for Pharmaceutical Medicine | Directeur/Membre du Conseil | - |
Swedish Pharmaceutical Society | President | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
34
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CaptiGel AB
 CaptiGel AB BiotechnologyHealth Technology Provides patented technological platform | Health Technology |
Abbott Scandinavia AB
Abbott Scandinavia AB Abbott Scandinavia AB provides information on Rybelsus, the first approved oral GLP-1 receptor agonist containing semaglutide, used to treat adults with type 2 diabetes when diet and exercise alone are insufficient to control blood sugar levels. Abbott Scandinavia focuses on diabetes care and weight management, providing educational resources to patients and healthcare providers about Rybelsus’s benefits, risks, and practical considerations. The company is based in Solna, Sweden. Rybelsus works by mimicking a gut hormone to increase insulin secretion and reduce glucagon, thereby lowering blood sugar, and has also been shown to support weight loss when combined with lifestyle changes. The Swedish company ’ s content highlights the medication ’ s dosing regimen, potential side effects, precautions, and alternatives such as injectable semaglutide products. | |
Foundation for Pharmaceutical Medicine | |
Swedish Pharmaceutical Society | |
AbbVie AB
AbbVie AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research and development pharmaceutical company | Commercial Services |
Double Bond Pharmaceutical International AB
 Double Bond Pharmaceutical International AB BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Hlt Konsult AB |
